Our mission at Synta is to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We aim to create the best place for the best people to create breakthrough drugs that change medical practice.
Our drug candidates have been discovered and developed internally. We have a unique chemical compound library, consisting of proprietary compounds collected over two decades from industrial and academic sources not typically found at pharmaceutical firms. We start with compounds from this library and use a variety of techniques to optimize promising lead compounds and generate new drug candidates. We currently have over 900 issued patents and pending applications worldwide covering our technology and drug candidates.
Our lead anti-cancer drug candidate, ganetespib, has been studied in approximately 1200 patients in more than 25 clinical trials. In preclinical models, ganetespib inhibits a molecular chaperone called Hsp90, essential to the function of many of the most fundamental drivers of cancer cell growth and proliferation. Treatment with ganetespib has been shown in preclinical models to reduce some aggressive features of tumors, such as the ability to induce the growth of new blood vessels (angiogenesis), to spread to other organs in the body (metastasis), and to resist attack by traditional therapies (chemo-resistance).